Document is current
Any future updates will be listed below
-
Authors
Gunther, Katherine
Profeta, Victoria
Keita, Medina
Park, Courtney
Wells, McKenzie
Sharma, Sonal
Schadt, Kimberly
Lynch, David R. https://orcid.org/0000-0001-7168-214X
-
Funding
Funding for this research was provided by:
Friedreich's Ataxia Research Alliance
- License Information
-
More Information
Article History
Received: 24 February 2025
Accepted: 4 April 2025
First Online: 30 April 2025
Declarations
:
: David Lynch receives grants from Reata/Biogen pharmaceuticals for performance of the MOXIE and planned studies of omaveloxolone. He also receives grants from Larimar, PTC, Neurocrine, Solid Biosciences, the NIH, FDA, FARA and MDA. Katherine Gunther, Victoria Profeta, Medina Keita, Courtney Park, McKenzie Wells, Sonal Sharma, and Kimberly Schadt have nothing to disclose.
: The study was approved through the CHOP IRB as study 2609 and performed in accordance with the Helsinki Declaration of 1964. All subjects provided informed consent to participate in the study.
